Nabriva Corporate
Go to...
  • Home
  • About Nabriva
    • Our Products
    • Named Patient Program
    • Meet the Team
  • pipeline & research
    • Fosfomycin
    • pleuromutilins
  • For Investors
    • Events & Presentations
    • Press Releases
    • Financial Performance
    • Share Performance
    • Shareholder Information
    • Corporate Governance
  • News & Publications
  • careers
  • contact us
  • Nabriva US
  • News & Publications
  • Careers
  • Contact Us
Nabriva Corporate
  • Home
  • About Nabriva
    • Our Products
    • Named Patient Program
    • Meet the Team
  • pipeline & research
    • Fosfomycin
    • pleuromutilins
  • For Investors
    • Events & Presentations
    • Press Releases
    • Financial Performance
    • Share Performance
    • Shareholder Information
    • Corporate Governance
  • News & Publications
  • careers
  • contact us

Named Patient Program

Home / About Nabriva / Named Patient Program
   
   
   
   
   
   

 

 

As part of our mission to support patients on a global scale, Nabriva is providing a Named Patient Program (NPP) to supply XENLETA® (lefamulin) to Healthcare Professionals (HCPs) in certain countries where XENLETA is not yet available.

The NPP is designed to ensure that physicians can request IV or oral XENLETA on behalf of patients who meet the necessary eligibility criteria and who live in certain countries where it is not yet available.

Nabriva has partnered with WEP Clinical, a UK-based pharmaceutical services company, to provide this program.  Under the terms of the NPP, XENLETA will be made available to patients in two formulations - 150mg injection for intravenous administration and 600mg oral tablets.  WEP Clinical is authorized to distribute XENLETA on a named patient basis but is not involved in the patient-doctor relationship. WEP Clinical is only permitted to distribute in response to an unsolicited physician request which has been reviewed and meets the necessary eligibility criteria.  Once a request is approved, WEP Clinical will manage the distribution of XENLETA to the treating physician and will provide any necessary follow-up support and services. 

For further information on the XENLETA Named Patient Program, please contact:

XENLETA NPP Contact Number: +44 207 887 2235

XENLETA NPP Email Address: xenletaNPP@wepclinical.com

 

Nabriva logo
  • Privacy Notice
  • Accessibility Statement
  • Patents
  • Imprint
  • Disclaimer
  • Contact Us
  • Careers
  • Sitemap

© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland

  • Privacy Notice
  • Accessibility Statement
  • Patents
  • Imprint
  • Disclaimer
  • Contact Us
  • Careers
  • Sitemap
Nabriva logo

© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland